Wednesday, 24 Apr 2019

You are here

Improved Mortality Trends in Lupus Nephritis

The mortality rate from end- stage renal disease (ESRD) in lupus nephritis (LN) patients has significantly decreased in the last decade.

Noting studies that showed premature mortality among ESRD lupus nephritis patients, researchers set out to examine if these trends have continued. Using national registry data through 2014, they studied 20,974 patients with incident ESRD due to LN between January 1, 1995 and December 31, 2014 and examined outcomes in 5-year blocks (1995–1999, 2000–2004, 2005–2009, 2010–2014).

Between 1995 through 2014, the mortality rate per 100 patient- years declined steadily:

  • 1995–1999 - 11.1 (95% confidence interval [95% CI] 10.4–11.8)
  • 2010–2014 - 6.7 (95% CI 6.2–7.2) (P trend < 0.01).

Compared with 1995–1999, the adjusted mortality hazard ratios in 2010–2014 were lower for whites (0.68;0.58–0.78), African Americans (0.67; 0.57–0.78), and for Hispanics (0.51; 0.38–0.69).

Deaths from cardiovascular disease (CVD) and infection declined by 44% and 63%, over this same period (p< 0.01 for both).

It appears that improving care in this high- risk population has lead to a reduction in all- cause mortality among white, African American, and Hispanic patients, with reduced risk of death from CVD and infection. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Improved Survival in Lupus

A longitudinal study of systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic has shown that mortality has decreased over time.

The cohort incuded 1732 SLE patients followed between 1971 and 2013. The cause of death was gleaned from death certificates, autopsy reports, hospital records or the records of the family physicians.  

EULAR 2019 Update to Lupus Management

The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.

Mortality Risk Factors in Systemic Sclerosis

A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.

In addition to a multicenter prospective study, investigators performed a metanalysis on SSc standarized mortality ratios (SMR) and hazard ratios of prognosis factors.

Better Tests Ahead in Lupus

The advent of "big data" and "-omics" technologies offers hope that clinicians will soon have better diagnostics for systemic lupus erythematosus, rheumatologists here were told.

GCA Relapse Risk High with Steroids

Prior to the introduction of tocilizumab to manage giant cell arteritis (GCA), glucocorticoids (GC) have been the mainstay of therapy, but has been limited by relapses in disease. A recent metanalysis shows that relapses occur in nearly half of patients and are related to the duration of therapy rather than the initial dose of GC.

A literature review found 34 studies (2,505 patients) from 8 RCTs of GCA patients only treated with GC.